Medivation Inc. (NASDAQ: MDVN) is a classic Wall Street success story. Founded by a group of experienced professionals, the company acquired early stage pharmaceuticals and medical devices that had promising clinical, intellectual property and commercial prospects and grew from just $5.00 per share in 2010 to more than $40.00 per share three years later. The majority of this growth happened in late 2011/early 2012, when the stock appreciated nearly 500% after successful clinical trials unlocked significant value in its product pipeline. 
Behind the scenes of this success, was biotech investment fund manager Fred Knoll, via his firm Knoll Capital Management, as a key investor. The fund began building a stake in the company in early 2006, where it acquired about $7.2 million worth of stock, according to regulatory filings. By the same time in 2007, the fund had more than doubled its share ownership and the $66 million position became the largest in its portfolio. And, according to the fund’s most recent regulatory filings, the stake is now worth more than $130 million today.